66504-19-6

Basic information

• Product Name: ethyl α-bromo-(4-trifluoromethylphenyl)acetate
• Synonyms: ethyl α-bromo-(4-trifluoromethylphenyl)acetate
• CAS NO: 66504-19-6
• Molecular Weight: 311.098
• Mol File: 66504-19-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: ethyl α-bromo-(4-trifluoromethylphenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl α-bromo-(4-trifluoromethylphenyl)acetate(66504-19-6)
• EPA Substance Registry System: ethyl α-bromo-(4-trifluoromethylphenyl)acetate(66504-19-6)

Safety Data

• Hazardous Substances Data: 66504-19-6(Hazardous Substances Data)

Upstream product

• 74426-51-0 4-(trifluoromethyl)phenylacetyl chloride 
• 32857-62-8 4-Trifluoromethylphenylacetic acid 
• 721-63-1 (4-trifluoromethylphenyl)acetic acid ethyl ester 

Downstream Products

• 721-63-1 (4-trifluoromethylphenyl)acetic acid ethyl ester 

Relevant articles and documents

SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions

Nuclear factor erythroid 2-related factor 2 (NRF2) is a pleiotropic transcription factor which regulates the constitutive and inducible transcription of a wide array of genes and confers protection against a variety of pathologies. Directly disrupting Kelch-like ECH-associated protein 1 (KEAP1)-NRF2 protein-protein interaction (PPI) has been explored as a promising strategy to activate NRF2. We reported here the first identification of a series of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 inhibitors. Our efforts led to the potent small molecule KEAP1-NRF2 inhibitor, 20c, which exhibited a Kd of 24 nM to KEAP1 and an IC50 of 75 nM in disrupting KEAP1-NRF2 interaction. Subsequent biological studies provided consistent evidence across mouse macrophage cell-based and in vivo models that 20c induced NRF2 target gene expression and enhanced downstream antioxidant and anti-inflammatory activities. Our study not only demonstrated that small molecule KEAP1-NRF2 PPI inhibitors can be potential preventive and therapeutic agents for diseases and conditions involving oxidative stress and inflammation but also enriched the chemical diversity of the KEAP1-NRF2 inhibitors.

INHIBITORS OF HIF PROLYL HYDROXYLASE

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.